Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Health-Related Quality of Life (HRQoL) in Patients with Relapsed/Refractory Follicular Lymphoma (R/R FL) Treated with Zanubrutinib+ Obinutuzumab Versus Obinutuzumab Monotherapy: The Rosewood Trial

Judith Trotman, Pier Luigi Zinzani, Yuqin Song, Richard Delarue, Gisoo Barnes, Pil Kim, Elena Ivanova, Boxiong Tang, Jiří Mayer, Ana C. De Oliveira, Sarit Assouline, Christopher R. Flowers

Blood (2023) 142 (Supplement 1): 1674.

https://doi.org/10.1182/blood-2023-181195

Published: 2023

Journal Articles

Real-World Treatment Patterns, Adherence and Healthcare Resource Utilization for Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia Among Veterans in the United States

Keri Yang, Sizhu Liu, Boxiong Tang, Asher Chanan-Khan

Blood (2021) 138 (Supplement 1): 4079.

https://doi.org/10.1182/blood-2021-148716

Published: 2021

Journal Articles

Real-World Testing Patterns for Risk Assessment and Implications on the Adoption of Novel Therapeutics in Chronic Lymphocytic Leukemia: IGHV Mutation Status, FISH Cytogenetic, and Immunophenotyping

Asher Chanan-Khan, Keri Yang, Tom Liu, Todd Zimmerman, Boxiong Tang, Sikander Ailawadhi

Blood (2021) 138 (Supplement 1): 4078.

https://doi.org/10.1182/blood-2021-147955

Published: 2021

Journal Articles

Impact of Atrial Fibrillation on Cardiovascular and Economic Outcomes in Patients with Chronic Lymphocytic Leukemia

Anjana Mohan, Keri Yang, Sizhu Liu, Randall Dick, Boxiong Tang, Asher Chanan-Khan

Blood (2021) 138 (Supplement 1): 4077.

https://doi.org/10.1182/blood-2021-148600

Published: 2021

Journal Articles

Real-World Evidence on Shift in Treatment Practice and Adoption of Novel Agents for Patients with Chronic Lymphocytic Leukemia in the United States

Asher Chanan-Khan, Keri Yang, Sizhu Liu, Todd Zimmerman, Boxiong Tang, Sikander Ailawadhi

Blood (2021) 138 (Supplement 1): 5013.

https://doi.org/10.1182/blood-2021-148736

Published: 2021

Journal Articles

Productivity Loss and Indirect Costs Among Non-Hodgkin Lymphoma Patients and Their Caregivers

Keri Yang, Sizhu Liu, Debra Irwin, Elizabeth Packnett, Carolyn R. Lew, Virginia Noxon, Boxiong Tang, Asher Chanan-Khan

Blood (2021) 138 (Supplement 1): 4009.

https://doi.org/10.1182/blood-2021-148443

Published: 2021

Journal Articles

Factors Associated with Treatment Among Older Adults Diagnosed with Chronic Lymphocytic Leukemia: An Analysis Using Medicare Claims Data

Eberechukwu Onukwugha, Tsung-Ying Lee, Johnson Abree, Catherine Cooke, Summers Amanda, Keri Yang, Sizhu Liu, Boxiong Tang, Yared Jean

Blood (2021) 138 (Supplement 1): 1968.

https://doi.org/10.1182/blood-2021-148727

Published: 2021

Journal Articles

Real-World Bruton Tyrosine Kinase Inhibitor Treatment Patterns, Compliance, Costs, and Hospitalizations in Patients with Mantle Cell Lymphoma in the United States

Bijal D. Shah, Keri Yang, Sizhu Liu, Jai Sivanantham, Yasser Ali, Chris Casten, Swaroop Satya, Boxiong Tang

Blood (2021) 138 (Supplement 1): 3046.

https://doi.org/10.1182/blood-2021-148053

Published: 2021

Journal Articles

Real-World Disease Burden, Costs and Resource Utilization of Hospital-Based Care Among Mantle Cell Lymphoma, Waldenström Macroglobulinemia, Marginal Zone Lymphoma and Chronic Lymphocytic Leukemia: Disparities and Risk Factors

Asher Chanan-Khan, Keri Yang, Sizhu Liu, Zhun Cao, Dorothy Baumer, Shanthi Krishnaswami, Boxiong Tang, Sikander Ailawadhi

Blood (2021) 138 (Supplement 1): 3048.

https://doi.org/10.1182/blood-2021-148633

Published: 2021

Journal Articles

A Clinical Practice Comparison of Overall Survival, Time-to-Next-Treatment, and Time-to-Treatment-Discontinuation Among CLL/SLL Patients Receiving First-Line Ibrutinib with and without a Del(17p) Mutation

Anthony Mato, MD, Boxiong Tang, MD PhD, Soraya Azmi, MBBS,MPH, Keri Yang, PhD MPH, MS, Jennifer C Stern, PhD, Eric Hedrick, MD, Jane Huang, MD, Jeff P Sharman, MD

Blood (2020) 136 (Supplement 1): 1–3.

https://doi.org/10.1182/blood-2020-134119

Published: 2020

Journal Articles

A Systematic Review of the Epidemiology and Economic Burden of Mantle Cell Lymphoma (MCL)

Keri Keri Yang, Eleanor Lucas, BA, Beth Lesher, PharmD, Tony Caver, PhD, Boxiong Tang, MD PhD

Blood (2019) 134 (Supplement_1): 5831.

https://doi.org/10.1182/blood-2019-129677

Published: 2019

Journal Articles

Systematic Literature Review on Global Real-World Treatment Patterns of Mantle Cell Lymphoma (MCL)

Keri Keri Yang, Beth Lesher, PharmD, Eleanor Lucas, BA, Tony Caver, PhD, Boxiong Tang, MD PhD

Blood (2019) 134 (Supplement_1): 5881.

https://doi.org/10.1182/blood-2019-130896

Published: 2019

Journal Articles

Real-World Healthcare Resource Utilization in Patients with Indolent Non-Hodgkin's Lymphoma: Differences between Patients Treated First-Line with Ibrutinib or Bendamustine + Rituximab

Debra Irwin, Lu Zhang, ScD, Kathleen Wilson, MPH, Gerard Hoehn, PhD, Erika Szabo, Boxiong Tang, MD PhD

Blood (2018) 132 (Supplement 1): 3549.

https://doi.org/10.1182/blood-2018-99-113093

Published: 2018

Journal Articles

Assessing the Need for a Biosimilar: A Systematic Literature Review of the Treatment Burden of Rituximab in Hematological Malignancies

Elizabeth James, Holly Trautman, Gerard Hoehn, PhD, Erika Szabo, Boxiong Tang, MD PhD

Blood (2018) 132 (Supplement 1): 5908.

https://doi.org/10.1182/blood-2018-99-110953

Published: 2018

Journal Articles

Real-World Healthcare Resource Utilization in Patients with Chronic Lymphocytic Lymphoma: Differences between Patients Treated with Ibrutinib or Bendamustine + Rituximab

Debra Irwin, Lu Zhang, ScD, Kathleen Wilson, MPH, Gerard Hoehn, PhD, Erika Szabo, Boxiong Tang, MD PhD

Blood (2018) 132 (Supplement 1): 3548.

https://doi.org/10.1182/blood-2018-99-112626

Published: 2018

Journal Articles

Comparative Cost-Efficiency Analysis of Granulocyte Colony-Stimulating Factors for Use in Chemotherapy Patients in the United States

Elizabeth James, Holly Trautman, Erika Szabo, Boxiong Tang, MD PhD

Blood (2017) 130 (Supplement 1): 4667.

https://doi.org/10.1182/blood.V130.Suppl_1.4667.4667

Published: 2017

Journal Articles

Budget Impact Analysis of Switching Chemotherapy Patients Using Granulocyte Colony-Stimulating Factors (G-CSFs) from Pegfilgrastim to Short-Acting G-CSFs in the United States

Elizabeth James, Holly Trautman, Erika Szabo, Boxiong Tang, MD PhD

Blood (2017) 130 (Supplement 1): 4668.

https://doi.org/10.1182/blood.V130.Suppl_1.4668.4668

Published: 2017

Journal Articles

Real-World Characteristics of CLL Patients Receiving Front-Line Therapy, Using the Flatiron Health Database

Boxiong Tang, MD PhD, Erika Szabo, Jifang Zhou, MD, Jerry Wu, Danielle M. Brander, MD

Blood (2017) 130 (Supplement 1): 4671.

https://doi.org/10.1182/blood.V130.Suppl_1.4671.4671

Published: 2017

Journal Articles

Length of Stay for Hospitalized Patients Treated with Ibrutinib or Bendamustine First-Line Therapy for Treatment of Chronic Lymphocytic Leukemia

Debra Irwin, Erika Szabo, Ashutosh Pathak, Boxiong Tang, MD PhD

Blood (2017) 130 (Supplement 1): 5618.

https://doi.org/10.1182/blood.V130.Suppl_1.5618.5618

Published: 2017

Journal Articles

Differences in Healthcare Utilization in CLL Patients Treated with BR Versus FCR

Susan Gabriel, Erika Szabo, Francesco Lo-Coco, Jifang Zhou, Boxiong Tang, Ashutosh Pathak

Blood (2016) 128 (22): 2406.

https://doi.org/10.1182/blood.V128.22.2406.2406

Published: 2016

NARROW

Health-Related Quality of Life (HRQoL) in Patients with Relapsed/Refractory Follicular Lymphoma (R/R FL) Treated with Zanubrutinib+ Obinutuzumab Versus Obinutuzumab Monotherapy: The Rosewood Trial

Real-World Treatment Patterns, Adherence and Healthcare Resource Utilization for Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia Among Veterans in the United States

Real-World Testing Patterns for Risk Assessment and Implications on the Adoption of Novel Therapeutics in Chronic Lymphocytic Leukemia: IGHV Mutation Status, FISH Cytogenetic, and Immunophenotyping

Impact of Atrial Fibrillation on Cardiovascular and Economic Outcomes in Patients with Chronic Lymphocytic Leukemia

Real-World Evidence on Shift in Treatment Practice and Adoption of Novel Agents for Patients with Chronic Lymphocytic Leukemia in the United States

Productivity Loss and Indirect Costs Among Non-Hodgkin Lymphoma Patients and Their Caregivers

Factors Associated with Treatment Among Older Adults Diagnosed with Chronic Lymphocytic Leukemia: An Analysis Using Medicare Claims Data

Real-World Bruton Tyrosine Kinase Inhibitor Treatment Patterns, Compliance, Costs, and Hospitalizations in Patients with Mantle Cell Lymphoma in the United States

Real-World Disease Burden, Costs and Resource Utilization of Hospital-Based Care Among Mantle Cell Lymphoma, Waldenström Macroglobulinemia, Marginal Zone Lymphoma and Chronic Lymphocytic Leukemia: Disparities and Risk Factors

A Clinical Practice Comparison of Overall Survival, Time-to-Next-Treatment, and Time-to-Treatment-Discontinuation Among CLL/SLL Patients Receiving First-Line Ibrutinib with and without a Del(17p) Mutation

A Systematic Review of the Epidemiology and Economic Burden of Mantle Cell Lymphoma (MCL)

Systematic Literature Review on Global Real-World Treatment Patterns of Mantle Cell Lymphoma (MCL)

Real-World Healthcare Resource Utilization in Patients with Indolent Non-Hodgkin's Lymphoma: Differences between Patients Treated First-Line with Ibrutinib or Bendamustine + Rituximab

Assessing the Need for a Biosimilar: A Systematic Literature Review of the Treatment Burden of Rituximab in Hematological Malignancies

Real-World Healthcare Resource Utilization in Patients with Chronic Lymphocytic Lymphoma: Differences between Patients Treated with Ibrutinib or Bendamustine + Rituximab

Comparative Cost-Efficiency Analysis of Granulocyte Colony-Stimulating Factors for Use in Chemotherapy Patients in the United States

Budget Impact Analysis of Switching Chemotherapy Patients Using Granulocyte Colony-Stimulating Factors (G-CSFs) from Pegfilgrastim to Short-Acting G-CSFs in the United States

Real-World Characteristics of CLL Patients Receiving Front-Line Therapy, Using the Flatiron Health Database

Length of Stay for Hospitalized Patients Treated with Ibrutinib or Bendamustine First-Line Therapy for Treatment of Chronic Lymphocytic Leukemia

Differences in Healthcare Utilization in CLL Patients Treated with BR Versus FCR

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only